Acute, but not repeated, administration of the neurotensin NTS1 receptor agonist PD149163 decreases conditioned footshock-induced ultrasonic vocalizations in rats

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 49, Issue , 2014, Pages 78-84

  Prus, Adam J ^a   Hillhouse, Todd M ^b   LaCrosse, Amber L ^c  

^a NORTHERN MICHIGAN UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Anxiety; Buspirone; Neurotensin; PD149163; Ultrasonic vocalization

Indexed keywords

BUSPIRONE; HALOPERIDOL; N2 (2,6 DIAMINOHEXYL)LYSYLPROLYLTRYPTOPHYL 3 METHYLVALYLLEUCINE ETHYL ESTER; NEUROTENSIN; ANXIOLYTIC AGENT; NEUROLEPTIC AGENT; NEUROTENSIN RECEPTOR; NEUROTENSIN TYPE 1 RECEPTOR;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CONDITIONING; CONTROLLED STUDY; DOSE RESPONSE; FOOTSHOCK; MALE; NONHUMAN; RAT; REPEATED DRUG DOSE; TRANQUILIZING ACTIVITY; ULTRASOUND; VOCALIZATION; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; CATALEPSY; CHEMICALLY INDUCED; DRUG EFFECTS; DRUG TOLERANCE; ELECTRIC SHOCK; FEAR; WISTAR RAT;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIPSYCHOTIC AGENTS; BUSPIRONE; CATALEPSY; CONDITIONING (PSYCHOLOGY); DRUG TOLERANCE; ELECTROSHOCK; FEAR; HALOPERIDOL; MALE; NEUROTENSIN; RATS; RATS, WISTAR; RECEPTORS, NEUROTENSIN; VOCALIZATION, ANIMAL;

EID: 84890038321     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.11.011     Document Type: Article

References (42)

1. Ahlenius S., Hillegaart V. Involvement of extrapyramidal motor mechanisms in the suppression of locomotor activity by antipsychotic drugs: a comparison between the effects produced by pre- and post-synaptic inhibition of dopaminergic neurotransmission. Pharmacol Biochem Behav 1986, 24:1409-1415.
2. Alexander M.J., Leeman S.E. Widespread expression in adult rat forebrain of mRNA encoding high-affinity neurotensin receptor. J Comp Neurol 1998, 402:475-500.
3. Batten T.F.C., Gamboa-Esteves F.O., Saha S. Evidence for peptide co-transmission in retrograde- and anterograde-labelled central nucleus of amygdala neurones projecting to NTS. Auton Neurosci 2002, 98:28-32.
4. Binder E.B., Kinkead B., Owens M.J., Nemeroff C.B. Neurotensin and dopamine interactions. Pharmacol Rev 2001, 53:453-486.
5. Boules M., McMahon B., Warrington L., Stewart J., Jackson J., Fauq A., et al. Neurotensin analog selective for hypothermia over antinociception and exhibiting atypical neuroleptic-like properties. Brain Research 2001, 919:1-11.
6. Boules M., McMahon B., Wang R., Warrington L., Stewart J., Yerbury S., et al. Selective tolerance to the hypothermic and anticataleptic effects of a neurotensin analog that crosses the blood-brain barrier. Brain Res 2003, 987:39-48.
7. Brodkin J., Busse C., Sukoff S.J., Varney M.A. Anxiolytic-like activity of the mGluR5 antagonist MPEP: a comparison with diazepam and buspirone. Pharmacol Biochem Behav 2002, 73:359-366.
8. Brudzynski S.M., Chiu E.M. Behavioural responses of laboratory rats to playback of 22kHz ultrasonic calls. Physiol Behav 1995, 57:1039-1044.
9. Corley K.C., Phan T.H., Daugherty W.P., Boadle-Biber M.C. Stress-induced activation of median raphe serotonergic neurons in rats is potentiated by the neurotensin antagonist, SR 48692. Neurosci Lett 2002, 319:1-4.
10. De Vry J., Benz U., Schreiber R., Traber J. Shock-induced ultrasonic vocalization in young adult rats: a model for testing putative anti-anxiety drugs. European Journal of Pharmacology. 1993, 249:331-339.
11. Dilts R.P., Boadle-Biber M.C. Differential activation of the 5-hydroxytryptamine-containing neurons of the midbrain raphe of the rat in response to randomly presented inescapable sound. Neurosci Lett 1995, 199:78-80.
12. Dilts R.P., Novitzki M.R., Phan T.H., Corley K.C., Boadle-Biber M.C. Neurotensin inhibits the activation of midbrain serotonergic neurons produced by random inescapable sound. Brain Res 1996, 742:294-298.
13. Feifel D., Melendez G., Murray R.J., Tina Tran D.N., Rullan M.A., Shilling P.D. The reversal of amphetamine-induced locomotor activation by a selective neurotensin-1 receptor agonist does not exhibit tolerance. Psychopharmacology 2008, 200:197-203.
14. Feifel D., Goldenberg J., Melendez G., Shilling P.D. The acute and subchronic effects of a brain-penetrating, neurotensin-1 receptor agonist on feeding, body weight and temperature. Neuropharmacology 2010, 58:195-198.
15. Fitzpatrick K., Winrow C.J., Gotter A.L., Millstein J., Arbuzova J., Brunner J., et al. Altered sleep and affect in the neurotensin receptor 1 knockout mouse. Sleep 2012, 35:949-956.
16. Grimond-Billa S.K., Norman C.G.W.B., Cassaday H.J. Selectively increased trace conditioning under the neurotensin agonist PD 149163 in an aversive procedure in which SR 142948A was without intrinsic effect. J Psychopharmacol 2008, 22:290-299.
17. Hadden M.K., Orwig K.S., Kokko K.P., Mazella J., Dix T.A. Design, synthesis, and evaluation of the antipsychotic potential of orally bioavailable neurotensin (8-13) analogues containing non-natural arginine and lysine residues. Neuropharmacology 2005, 49:1149-1159.
18. Hertel P., Byskov L., Didriksen M., Arnt J. Induction of tolerance to the suppressant effect of the neurotensin analogue NT69L on amphetamine-induced hyperactivity. Eur J Pharmacol 2001, 422:77-81.
19. Hertel P., Olsen C.K., Arnt J. Repeated administration of the neurotensin analogue NT69L induces tolerance to its suppressant effect on conditioned avoidance behaviour. Eur J Pharmacol 2002, 439:107-111.
20. Holly E.N., Ebrecht B.E., Prus A.J. The neurotensin-1 receptor agonist PD149163 inhibits conditioned avoidance responding without producing catalepsy in rats. Eur Neuropsychopharmacol 2011, 21:526-531.
21. Jennes L., Stumpf W.E., Kalivas P.W. Neurotensin: topographical distribution in rat brain by immunohistochemistry. J Comp Neurol 1982, 210:211-224.
22. Jolas T., Aghajanian G.K. Neurotensin and the serotonergic system. Prog Neurobiol 1997, 52:455-468.
23. Kelly P.H., Seviour P.W., Iversen S.D. Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Res 1975, 94:507-522.
24. Meisenberg G., Simmons W.H. Motor hypoactivity induced by neurotensin and related peptides in mice. Pharmacol Biochem Behav 1985, 22:189-193.
25. Millan M.J., Brocco M., Gobert A., Dorey G., Casara P., Dekeyne A. Anxiolytic properties of the selective, non-peptidergic CRF(1) antagonists, CP154,526 and DMP695: a comparison to other classes of anxiolytic agent. Neuropsychopharmacology 2001, 25:585-600.
26. Molewijk H.E., van der Poel A.M., Mos J., van der Heyden J.A., Olivier B. Conditioned ultrasonic distress vocalizations in adult male rats as a behavioural paradigm for screening anti-panic drugs. Psychopharmacology 1995, 117:32-40.
27. National Research Council Guide for Laboratory Animal Facilities and Care 2011, National Research Council, Washington D.C. 8th ed.
28. Norman C., Beckett S.R., Spicer C.H., Ashton D., Langlois X., Bennett G.W. Effects of chronic infusion of neurotensin and a neurotensin NT1 selective analogue PD149163 on amphetamine-induced hyperlocomotion. J Psychopharmacol 2008, 22:300-307.
29. Petrie K.A., Bubser M., Casey C.D., Davis M.D., Roth B.L., Deutch A.Y. The neurotensin agonist PD149163 increases Fos expression in the prefrontal cortex of the rat. Neuropsychopharmacology 2004, 29:1878-1888.
30. Remy S.M., Schreiber R., Dalmus M., De Vry J. Somatodendritic 5-HT1A receptors are critically involved in the anxiolytic effects of 8-OH-DPAT. Psychopharmacology 1996, 125:89-91.
31. Rinkel G.J.E., Hoeke E.C., van Wimersma Greidanus T.B. Elective tolerance to behavioral effects of neurotensin. Physiol Behav 1983, 31:467-470.
32. Sanchez C., Meier E. Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike?. Psychopharmacology 1997, 129:197-205.
33. Sanchez C., Bergqvist P.B., Brennum L.T., Gupta S., Hogg S., Larsen A., et al. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology 2003, 167:353-362.
34. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van Gompel P., Lesage A.S., De Loore K., Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996, 124:57-73.
35. Shilling P.D., Feifel D. The neurotensin-1 receptor agonist PD149163 blocks fear-potentiated startle. Pharmacol Biochem Behav 2008, 90:748-752.
36. Shugalev N.P., Stavrovskaia A.V., Iamshchikova N.G. Effect of neurotensin on the behavior of rats with damaged serotoninergic neurons under immobilization stress. Zh Vyssh Nerv Deiat Im I P Pavlova 2005, 55:671-676.
37. St-Galais F., Jomphe C., Trudeau L.-E. The role of neurotensin in central nervous system pathophysiology: What is the evidence?. J Psychatry Neurosci. 2006, 31:229-245.
38. Sun T., He W., Hu G., Li M. Anxiolytic-like property of risperidone and olanzapine as examined in multiple measures of fear in rats. Pharmacol Biochem Behav 2010, 95:298-307.
39. Tonoue T., Ashida Y., Makino H., Hata H. Inhibition of shock-elicited ultrasonic vocalization by opioid peptides in the rat: a psychotropic effect. Psychoneuroendocrinology 1986, 11:177-184.
40. Tonoue T., Iwasawa H., Naito H. Diazepam and endorphin independently inhibit ultrasonic distress calls in rats. Eur J Pharmacol 1987, 142:133-136.
41. Tornatzky W., Miczek K.A. Behavioral and autonomic responses to intermittent social stress: differential protection by clonidine and metoprolol. Psychopharmacology 1994, 116:346-356.
42. Wang R., Boules M., Gollatz E., Williams K., Tiner W., Richelson E. Effects of 5 daily injections of the neurotensin-mimetic NT69L on the expression of neurotensin receptors in rat brain. Mol Brain Res 2005, 138:24-34.